stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Shares outstanding
Oruka Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $45.6M, up 171.7% from $16.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $62.9M. Over the past ten years it has ranged from $29.1K (fiscal 2015) to $45.6M (fiscal 2025) — the current reading is the highest in ten years. Oruka Therapeutics, Inc. ranks 245th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $45.6M | 171.68% |
| FY2024 | $16.8M | 1,298.18% |
| FY2023 | $1.2M | 0.03% |
| FY2022 | $1.2M | 3.64% |
| FY2021 | $1.2M | 195.23% |
| FY2020 | $392.3K | 256.64% |
| FY2019 | $110.0K | 71.61% |
| FY2018 | $64.1K | 32.71% |
| FY2017 | $48.3K | 15.00% |
| FY2016 | $42.0K | 44.33% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $62.9M | 13.96% |
| Mar 2026 | $55.2M | 20.95% |
| Dec 2025 | $45.6M | 3.51% |
| Sep 2025 | $44.1M | 4.68% |
| 42 more quarters | Free account |
Against its own ten years
Low $29.1K
High $45.6M
Ten-year median
$392.3K
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| ORKA Oruka Therapeutics, Inc. | $62.9M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| AXSM Axsome Therapeutics, Inc. compare | $52.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item